A crossover, randomized, single-masked study which compares the short-term (3 months) 24-hour IOP control and safety of travoprost/timolol fixed combination given once in the evening, versus that of latanoprost/timolol fixed combination given once in the evening in patients with exfoliative glaucoma. The primary objective of this trial is to compare the quality of 24-hour IOP control after 3 months of chronic therapy with these two medications.

• Drug: treatment with latanoprost/timolol fixed combination
• Drug: latanoprost/timolol fixed combination drops

• Active Comparator: treatment with travoprost/timolol fixed combination drops once in the evening
• Active Comparator: Treatment with latanoprost/timolol fixed combination

Inclusion Criteria:

• Patient has XFG and is older than 29 years
• The IOP without treatment is greater than 25 mm Hg and lower than 40 mm Hg at baseline (2 readings at 10:00)
• Patient can be safely washed out without risk for significant deterioration
• Distance best corrected Snelen visual acuity better than 0.1
• No contraindication to prostaglandins or β-blockers
• No history of lack of response (<10% reduction) to any medication
• Patient can understand the instructions and comply to medications
• Open normal appearing angles
• No sign of ocular infection, except blepharitis, corneal abnormality that may affect IOP measurements etc

Exclusion Criteria:

• History of trauma, inflammation, surgery, past use of steroids (within 2 months), severe dry eyes and use of contact lenses
• Patient is a female of childbearing potential or lactating mother